×

Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes

BAGSVAERD, Denmark, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks.

Further information

Media:
Mike Rulis +45 3079 3573 mike@novonordisk.com


Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company announcement No 14 / 2015

Company announcement No 14 / 2015 http://hugin.info/2013/R/1896081/672652.pdf

HUG#1896081

Source:Novo Nordisk A/S